Association between disease-modifying antirheumatic drugs and diabetes risk in patients with rheumatoid arthritis and psoriasis Full Text
JAMA,  Clinical Article

Solomon DHet al. – Among patients with RA or psoriasis, the adjusted risk of DM was lower for individuals starting a TNF inhibitor or hydroxychloroquine compared with initiation of other nonbiologic DMARDs.

Methods

  • Retrospective cohort study among 121 280 patients with diagnosis of either RA or psoriasis on at least 2 visits
  • Analyses conducted in context of 2 large health insurance programs, 1 in Canada and 1 in the United States, using administrative data
  • Mean follow-up 5.8 months and began with first prescription for DMARD after study eligibility was met
  • Drug regimens categorized into 4 mutually exclusive groups: (1) tumor necrosis factor (TNF) inhibitors with or without other DMARDs; (2) methotrexate without TNF inhibitors or hydroxychloroquine; (3) hydroxychloroquine without TNF inhibitors or methotrexate; or (4) other nonbiologic DMARDs without TNF inhibitors, methotrexate, or hydroxychloroquine (reference exposure)

Results
  • 13,905 participants with 22,493 treatment episodes starting 1 of the categories of DMARD regimens between January 1996 and June 2008
  • New diabetes cases and respective incidence rates per 1000 person-years were: other nonbiologic DMARDs (55 cases among 3993 treatment episodes; rate, 50.2; 95% confidence interval [CI], 47.3-53.2); TNF inhibitors (80 cases among 4623 treatment episodes; rate, 19.7; 95% CI, 19.1-20.3); methotrexate (82 cases among 8195 treatment episodes; rate, 23.8; 95% CI, 23.0-24.6); and hydroxychloroquine (50 cases among 5682 treatment episodes; rate, 22.2; 95% CI, 21.3-23.1)
  • Multivariate adjusted HR for DM 0.62 (95% CI, 0.42-0.91) for TNF inhibitors, 0.77 (95% CI, 0.53-1.13) for methotrexate, and 0.54 (95% CI, 0.36-0.80) for hydroxychloroquine compared with other nonbiologic DMARDS

Please login or register to follow this author.
► Click here to access Full Text, PubMed, Publisher and related articles...
<< Previous Article | Next Article >>

Your Unread Messages in Rheumatology

See All >> Messages include industry-sponsored communications and special communications from MDLinx

Most Popular Rheumatology Articles

1 Coffee or tea consumption and the risk of rheumatoid arthritis: A meta-analysis Clinical Rheumatology, October 15, 2014    Clinical Article

2 Mayo Clinic researchers: TNF inhibitors may increase cancer risk in the eye Mayo Clinic, November 19, 2014

3 Homeopathy in the treatment of fibromyalgia- A comprehensive literature-review and meta-analysis Complementary Therapies in Medicine, August 15, 2014    Evidence Based Medicine    Review Article

4 Blood test could prevent medication trial and error for rheumatoid arthritis patients Mayo Clinic, November 18, 2014

5 Comparison of the effects of three oral bisphosphonate therapies on the peripheral skeleton in postmenopausal osteoporosis: The TRIO study Osteoporosis International, November 12, 2014    Clinical Article

6 Adalimumab for steroid sparing in patients with giant-cell arteritis: Results of a multicentre randomised controlled trial Annals of Rheumatic Diseases, November 10, 2014    Clinical Article

7 New treatments for inflammatory rheumatic disease Immunologic Research, November 17, 2014    Review Article

8 Rituximab vs mycophenolate and vs cyclophosphamide pulses for induction therapy of active lupus nephritis: A clinical observational study Rheumatology, February 11, 2014    Clinical Article

9 Sustained remission with etanercept tapering in early rheumatoid arthritis New England Journal of Medicine, November 10, 2014    Evidence Based Medicine    Clinical Article

10 The comparative safety of TNF inhibitors in rheumatoid arthritis - a meta-analysis update of 44 randomized controlled trials American Journal of Medicine, October 6, 2014    Clinical Article

11 Importance of methotrexate therapy concomitant with tocilizumab treatment in achieving better clinical outcomes for rheumatoid arthritis patients with high disease activity: An observational cohort study Rheumatology, August 12, 2014    Clinical Article

12 Three decades of low-dose methotrexate in rheumatoid arthritis: Can we predict toxicity? Immunologic Research, November 17, 2014    Review Article    Clinical Article

13 Comparison of the efficacy, adverse effects and cost of zoledronic acid and denosumab in the treatment of osteoporosis Endocrine Practice, November 7, 2014    Review Article

14 Clinical and radiographic outcomes at 2 years and the effect of tocilizumab discontinuation following sustained remission in the second and third year of the ACT-RAY study Annals of Rheumatic Diseases, November 18, 2014    Clinical Article

15 A double-blind, placebo-controlled, randomized, 12-week, dose-ranging study of VX-509 (decernotinib), an oral selective janus kinase 3 (JAK3) inhibitor, as monotherapy in patients with active rheumatoid arthritis Arthritis & Rheumatism, November 14, 2014    Clinical Article

16 Yearly treatment could slow osteoarthritis Monash University News, September 23, 2014

17 Intra articular injection with corticosteroids in patients with recent onset rheumatoid arthritis: subanalyses from the BeSt study Clinical Rheumatology, February 17, 2014    Clinical Article

18 Efficacy and safety of olokizumab in patients with rheumatoid arthritis with an inadequate response to TNF inhibitor therapy: Outcomes of a randomised Phase IIb study Annals of Rheumatic Diseases, August 12, 2014    Clinical Article

19 Drug-associated cutaneous vasculitis: Study of 239 patients from a single referral center The Journal of Rheumatology, September 25, 2014    Clinical Article

20 Study by UCLA scientists reveals new findings about cause of lesions around jaw bone UCLA Health System, November 26, 2014

Indexed Journals in Rheumatology: Arthritis & Rheumatism, Annals of Rheumatic Diseases, Journal of Rheumatologymore